Torrent Pharmaceuticals declared its Q3 FY26 financial results on February 13, 2026, reporting robust performance driven by its branded business. Net Profit after tax surged by 26% YoY to ₹635 crores for the quarter. The company also completed the acquisition of a 48.8% stake in JB Chemicals & Pharmaceuticals Ltd., which has resulted in consolidated results reflecting control from January 21, 2026. The standalone net profit for the quarter reached ₹577 crores.
Torrent Pharma Reports Strong Q3 FY26 Performance
Torrent Pharmaceuticals Limited announced its financial results for the quarter ended December 31, 2025, showcasing significant growth across key metrics. The results were approved by the Board of Directors on February 13, 2026.
Consolidated Financial Highlights (Q3 FY26 vs Q3 FY25)
The consolidated performance highlights robust operational efficiency:
- Revenues stood at ₹3,303 crores, marking an 18% YoY increase.
- Operating EBITDA reached ₹1,088 crores, up 19% YoY, with the Operating EBITDA margin maintained at 33%.
- Gross Margin for the quarter was reported at 76%.
- Net Profit After Tax (PAT) grew by a substantial 26% YoY to ₹635 crores.
For the nine months ended December 31, 2025, consolidated revenues grew 14% YoY to ₹9,783 crores, while PAT increased 26% YoY to ₹1,774 crores.
Standalone Financial Highlights (Q3 FY26 vs Q3 FY25)
On a standalone basis, the company reported:
- Total Income of ₹2,591 crores for the quarter.
- Net Profit for the quarter was ₹577 crores, compared to ₹485 crores in Q3 FY25.
- Basic and Diluted Earnings Per Share (EPS) for the quarter stood at ₹17.04, up from ₹14.33 YoY.
- For the nine months ended December 31, 2025, standalone EPS was ₹50.96.
Interim Dividend Recommendation
The Board of Directors has recommended an interim dividend of ₹29/- (580%) per equity share with a face value of ₹5 each. This dividend is expected to be paid/dispatched on or around March 6, 2026.
Update on JB Chemicals Acquisition
The financial results incorporate the impact of the acquisition of a controlling stake in JB Pharma, with control effective from January 21, 2026. The company acquired equity shares through an open offer, a purchase agreement with Tau Investment Holdings Pte. Ltd. (representing 46.39% stake), and agreements with employees (aggregating 2.41% stake).
Exceptional items for the quarter and nine months ended December 31, 2025, totaling ₹10 crores for the quarter, pertain to regulatory and statutory fees associated with this acquisition. The company is currently seeking necessary approvals for a proposed scheme of merger with JB Pharma.
Geographical Performance Highlights (9M FY26 vs 9M FY25)
The company provided key performance insights across major markets for the nine-month period:
India
- Revenues: ₹5,430 crores, growing by 12% YoY.
- IPM growth for the quarter was 10% (per AIOCD PharmaTrac data).
- Strong volume outperformance observed in Cardiac, Gastro, and Diabetes segments.
Brazil
- Revenues: ₹907 crores, up 21% YoY.
- Constant currency revenue growth of 13% (market growth 7%).
United States
- Revenues: ₹967 crores, up 21% YoY.
- Constant currency revenue grew 12% for the quarter.
Germany
- Revenues: ₹916 crores for 9M FY26, up 7% YoY.
- Growth remains impacted by supply disruption at a third-party supplier.
Company Profile Summary
Torrent Pharma is the flagship company of the Torrent Group, with annual revenues exceeding ₹11,500 crores. Post-acquisition, it is now ranked 5th in the Indian Pharmaceuticals Market. The company focuses primarily on chronic and sub-chronic therapies, accounting for approximately 76% of Indian revenues, and holds key therapeutic segment leadership positions.
Source: BSE
